Form 4: Aclaris Therapeutics Director William D. Humphries Acquires Stock Options and Restricted Stock Units

Director William D. Humphries of Aclaris Therapeutics acquired stock options and restricted stock units on June 6, 2024, as part of the company's non-employee director compensation policy.

Summary

• William D. Humphries, a director of Aclaris Therapeutics, acquired 15,750 stock options and 4,793 restricted stock units (RSUs) on June 6, 2024.
• The stock options have an exercise price of $1.03 and vest in twelve equal monthly installments starting July 6, 2024, contingent upon continuous service.
• The RSUs will vest on June 6, 2025, also subject to continuous service.
• These grants were made under the issuer's ninth amended and restated non-employee director compensation policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices that align director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The acquisition of stock options and RSUs by a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

This type of equity compensation is common for directors of publicly traded companies to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a standard practice in the pharmaceutical and biotechnology industries.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options and restricted stock units as part of their director compensation packages.
• The specific amounts and vesting schedules vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view this as a positive sign that the director's interests are aligned with theirs.
• Employees may see this as a standard practice for director compensation.

Key Dates